Reuters logo
10 个月内
BRIEF-Aurinia announces that voclosporin achieves endpoints in its Phase IIB Aura-LV Study
2016年9月29日 / 晚上9点02分 / 10 个月内

BRIEF-Aurinia announces that voclosporin achieves endpoints in its Phase IIB Aura-LV Study

1 分钟阅读

Sept 29 (Reuters) - Aurinia Pharmaceuticals Inc

* Comprehensive mortality review concludes deaths in aura-lv study appear to be unrelated to study drug and consistent with complications of ln

* Announces that Voclosporin achieves primary and all pre-specified secondary endpoints in its phase IIB Aura-LV study for Lupus Nephritis (ln) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below